COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes-Reference-Cited by-同舟云学术

COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes

Published:2022-02 Issue:7 Volume:40 Page:970-976
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Rolfes Leàn,Härmark Linda,Kant Agnes,van Balveren Leontine,Hilgersom Wil,van Hunsel Florence

Funder

Nederland Ministerie van Volksgezondheid Welzijn en Sport

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. European Medicines Agency EMA. SmPC Comirnaty; 2021 [updated 12-07-2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.

2. European Medicines Agency EMA. SmPC Spikevax; 2021 [updated 12-07-2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf.

3. European Medicines Agency EMA. SmPC Vaxzevria; 2021 [updated 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf.

4. European Medicines Agency EMA. SmPC Covid-19 vaccine Janssen; 2021 [updated 07-07-2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf.

5. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N Engl J Med.,2021

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cohort event monitoring of safety of COVID-19 vaccines: the Italian experience of the “ilmiovaccinoCOVID19 collaborating group”;Frontiers in Drug Safety and Regulation;2024-08-12

2. Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study;Eurosurveillance;2024-06-20

3. Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally;Vaccine: X;2024-06

4. Factors influencing adverse events following COVID-19 vaccination;Human Vaccines & Immunotherapeutics;2024-03-06

5. Audiovestibular adverse events following COVID-19 vaccinations;Vaccine;2024-03